Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B Clinical Trial

Official title:

A Comparative Randomized Double-Blind Study of Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® in Adult Study Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04209400
• Other study ID #: 38-13-040 RUS
• Status: Completed
• Phase: Phase 3
• Start date: April 18, 2014
• Est. completion date: April 20, 2015

Study information

• Verified date: March 2022
• Source: VBI Vaccines Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was a comparative, randomized, double-blind clinical study of the efficacy and safety of Sci-B-Vac® (10 μg dose) and the Engerix-B® (20 μg dose) vaccines in two parallel groups of hepatitis B-naive healthy adult subjects in Russia.

Description:

This study was a comparative randomized double-blind clinical study of the efficacy and safety of Sci-B-Vac® (10 μg dose) and the Engerix-B® (20 μg dose) vaccines in hepatitis B-naive healthy adult subjects (n = 100). The study was conducted at 3 study sites in the Russian Federation. Subjects who passed the screening successfully were randomized into two groups, Sci-B-Vac® (10 μg dose) and Engerix-B® (20 μg dose), in a 1:1 ratio. Subjects were vaccinated three times at days 1, 28, and 180 of the study.

Statistical Methods: Evaluation and comparison of immunogenicity were conducted at baseline, day 28, day 90 (60 days after the second vaccination), day 180 (prior to administering the third vaccine, 90 days after the second vaccination), and day 210 (30 days after the third vaccination) of the study.

The primary outcome was the seroconversion rate (proportion of subjects with anti-HBs levels ≥ 2.1 mIU/mL) after the third vaccination at day 210. The non-inferiority margin was set at 4%. The percentage of subjects who achieved seroconversion was analyzed using the Chi-square test for proportions along with the McNemar's test for repeated measurements in each group. The non-inferiority hypotheses were confirmed if the lower range of the confidence interval was at least -4%. The secondary endpoint was SPR (≥10 mIU/ml), measured at days 1, 28, 90, 180 and 210.

Demographic data, initial parameters, safety parameters, tolerance of the experimental vaccine, and other study parameters were analyzed using descriptive statistics (mean value, standard deviation, median, minimum and maximum values, range, quartiles, the number of valid cases-for quantitative variables; absolute number, proportion, allocation-for qualitative variables). A comparative assessment of the detection rate for different parameters in the two comparison groups was conducted using the Student's t-test; differences were considered statistically significant at a significance level of 5%. The assay used to measure anti-HBs concentrations had an upper limit of 1000 mIU/mL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: April 20, 2015
• Est. primary completion date: April 20, 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Availability of written Informed Consent to participate in the study from the subject.

2. Male or female between 18 and 45 years old without previous contact with hepatitis B virus (HBV).

3. Good health condition based on full physical examination.

4. Normal values of laboratory biochemical blood tests.

5. Seronegative with respect to anti-HBs (surface) antibodies, anti-HBc (core) antibodies, and HBs Antigen (HBsAg) on screening.

6. Not pregnant and not breast-feeding.

7. For men and women of reproductive age: consent for use of an effective contraception method, for example, an intrauterine device, oral contraceptive, hypodermic implant or double barrier method (a condom with contraceptive sponge or contraceptive suppository) throughout the entire study.

Exclusion Criteria:

1. Congenital or inherited immunodeficiency disorder in family history.

2. Information of a serious blood disorder, cardiac disorder, or tumour.

3. Current use of any medication that could alter immune reactivity.

4. Infection with HBV at the present time or in the past, confirmed by HBV markers test.

5. Anaphylaxis or severe allergy, or atopy, history of alcoholism or drug abuse.

6. Pregnancy and breast-feeding.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B

Intervention

Biological:
• Sci-B-Vac®
Sci-B-Vac® vaccine-10 µg of HBsAg, intramuscular injection of 10 µg/ml
• Engerix-B®
Engerix-B® vaccine-20 µg of HBsAg, intramuscular injection of 20 µg/ml

Locations

Country	Name	City	State
Russian Federation	Saint Petersburg State Budgetary Healthcare Institution	Saint Petersburg	Mirgorodskaya

Sponsors (1)

Lead Sponsor	Collaborator
VBI Vaccines Inc.

Country where clinical trial is conducted

Russian Federation, 

References & Publications (1)

Esaulenko EV, Yakovlev AA, Volkov GA, Sukhoruk AA, Surkov KG, Kruglyakov PV, Diaz-Mitoma F. Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation. Clin Infect Dis — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse Events: Local Reactions at the Injection Site- Incidence of Redness	Incidence of mild erythema at the injection site 1, 2 and 28 days after the first vaccination.	Day 1, Day 2, and Day 28
Other	Adverse Events: Local Reactions at the Injection Site - Incidence of Itch	Incidence of itchiness at the injection site at any point throughout the trial. Itchiness was assessed for 5 days following vaccinations on Days 1, 28, and 180 and also assessed on Day 90 and Day 210.	Days 1-5, Days 28-32, Day 90, Days 180-185, Day 210
Other	Adverse Events: Local Reactions at the Injection Site - Incidence of Pain	Incidence of pain at the injection site on the day of vaccination. Vaccination was performed on Day 1, Day 28, and Day 180.	Days 1, 28, 180
Other	Adverse Events: Local Reactions at the Injection Site - Intensity of Pain	Pain was evaluated 30 minutes after each vaccination by the subject using the visual analogue scale. A higher score indicates greater pain intensity.	Days 1, 28, 180
Primary	Seroconversion Rate	Percentage of subjects with an anti-HBs antibody level = 2.1 mIU/mL 30 days after the last of three vaccinations. Seroconversion is defined as the development of a detectable anti-HBs antibody level above an established threshold of 2.1 mIU/mL.	Day 210
Secondary	Seroprotection Rate	Percentage of subjects with an anti-HBs antibody level = 10 mIU/mL prior to vaccination, 28 days after the first vaccination, 60 and 150 days after the second vaccination and 30 days after the third vaccination. The development of an anti-HBs antibody level of at least 10 mIU/mL is an established surrogate of seroprotection and correlate of protective immunity against HBV.	Days 1, 28, 90, 180, 210
Secondary	Seroconversion Rate	Percentage of subjects with an anti-HBs antibody level = 2.1 mIU/mL prior to vaccination, 28 days after the first vaccination and 60 and 150 days after the second vaccination. Seroconversion is defined as the development of a detectable anti-HBs antibody level above an established threshold of 2.1 mIU/mL.	Days 1, 28, 90, 180
Secondary	Geometric Mean Concentrations (GMC) of HBs Antibodies	Geometric mean concentration of anti-HBs antibody in mIU/mL 28 days after the first vaccination, 60 and 150 days after the second vaccination, and 30 days after the third vaccination.	Days 1, 28, 90, 180, and 210

External Links

•   Link to full length manuscript